Comparative Pharmacology
Head-to-head clinical analysis: NESINA versus SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NESINA versus SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE.
NESINA vs SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing inactivation of incretin hormones (GLP-1, GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion, and suppressing glucagon release. Metformin reduces hepatic gluconeogenesis, decreases intestinal glucose absorption, and improves insulin sensitivity.
25 mg orally once daily.
Initial dose: 2.5 mg saxagliptin/500 mg metformin hydrochloride orally twice daily with meals. Titrate up to max 5 mg/1000 mg twice daily.
None Documented
None Documented
Terminal elimination half-life: 12.4–26.1 hours (mean ~21 hours); supports once-daily dosing
Saxagliptin: 2.5 hours; 5-hydroxy saxagliptin (active metabolite): 3.1 hours. Metformin: 4.5-6.2 hours. Total combined half-life 2-6 hours, requiring twice-daily dosing.
Renal: 87% (75% as unchanged drug, 12% as inactive metabolites); Fecal: <1%
Saxagliptin: 75% renal (50% unchanged, 25% as metabolite), 22% fecal. Metformin: 90-100% renal unchanged via tubular secretion.
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor